Physician profile
David D Ono
NPI 1073557096
$2,981.12
in general payments reported to CMS, 2019-2025
23 companies · $122 in 2025
The $122 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $58.54 · 2020: $159 · 2021: $392 · 2022: $660 · 2023: $1,086 · 2024: $503 · 2025: $122.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,678 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,678.18 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $661.49 | 2020-2024 | Tavneos, Parsabiv, Krystexxa |
| Astrazeneca Pharmaceuticals LP | $549.11 | 2019-2024 | Lokelma, Farxiga |
| Horizon Therapeutics Plc | $222.63 | 2020-2023 | Krystexxa |
| Takeda Pharmaceuticals U.S.A., INC. | $205.39 | 2021-2023 | Gattex |
| Novo Nordisk INC | $192.33 | 2020-2024 | Ozempic, Rybelsus |
| Akebia Therapeutics INC | $159.82 | 2020-2025 | Vafseo |
| Vifor Pharma, INC. | $147.47 | 2020-2024 | Veltassa |
| Nxstage Medical, INC. | $124.91 | 2021-2022 | |
| Ardelyx, INC. | $119.59 | 2024 | Xphozah 30 Mg |
| Baxter Healthcare | $115.00 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $77.10 | 2021-2023 | Jynarque |
| Calliditas Therapeutics US INC. | $67.64 | 2022-2023 | Tarpeyo |
| Ani Pharmaceuticals, INC. | $65.88 | 2022 | |
| Glaxosmithkline, LLC. | $45.63 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $44.53 | 2021-2023 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kyowa Kirin, INC. | $42.20 | 2023 | Crysvita |
| Travere Therapeutics, INC. | $28.14 | 2023 | |
| Alexion Pharmaceuticals, INC. | $23.13 | 2022 | |
| Aurinia Pharma U.S., INC. | $21.67 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.59 | 2023 | Jardiance |
| Fresenius USA Marketing, INC. | $17.97 | 2022 | |
| Mallinckrodt Hospital Products INC. | $16.86 | 2021 | |
| Allergan, INC. | $11.04 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Ono listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.